Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 4 1Phase 1/2 1Phase 1 1

Status

Recruiting 4Active not recruiting 3

Sponsor Class

INDUSTRY 5OTHER_GOV 1OTHER 1

Study Type

Interventional 7

Sponsor

Cancer Type

Genitourinary 7

Conditions

Prostatic Neoplasms 7Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 2Refractory or Relapsed Solid Tumors 1Prostatic Neoplasms, Castration-Resistant 1Non-metastatic Castration-resistant Prostate Cancer 1Metastatic Castration-resistant Prostate Neoplasms 1Metastatic Castration-resistant Prostate Cancer 1Bulbo-Spinal Atrophy, X-Linked 1Biochemically Recurrent Prostate Cancer 1Adenocarcinoma 1

Interventions

enzalutamide 21Magnetic Resonance Spectroscopy 21apalutamide 17Androgen Antagonists 14Specimen Handling 13Prednisone 13Abiraterone Acetate 13abiraterone 9Docetaxel 9Radiotherapy 8Biopsy 8darolutamide 7Radiosurgery 7Pluvicto 7Nivolumab 7cabazitaxel 6Lutetium-177 62-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 6Lutetium 5radium Ra 223 dichloride 4pembrolizumab 4niraparib 4gallium 68 PSMA-11 4cabozantinib 4bicalutamide 4atezolizumab 4Watchful Waiting 4Surveys and Questionnaires 4Standard of Care 4Radiotherapy, Intensity-Modulated 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Prostatic Neoplasms × darolutamide × 30 days × Clear all
NCT05997615 2026-06-04

AMX-500

Vir Biotechnology, Inc.

Phase 1 Recruiting
437 enrolled
Genitourinary

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT05367440 2026-06-01

PETRANHA

AstraZeneca

Phase 1/2 Active not recruiting
174 enrolled
Genitourinary

Prostatic Neoplasms

NCT07617272 2026-06-01

PARIS-BIO

Region Stockholm

Phase 2 Recruiting
100 enrolled
Genitourinary

Adenocarcinoma, Prostatic Neoplasms

NCT07611110 2026-05-28

VECTRA-01

AstraZeneca

Phase 3 Recruiting
670 enrolled
Genitourinary

Prostatic Neoplasms

NCT04070209 2026-05-27

Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X)

Sir Mortimer B. Davis - Jewish General Hospital

Phase 2 Active not recruiting
66 enrolled
Genitourinary

Prostatic Neoplasms

NCT06120491 2026-05-27

EvoPAR-PR01

AstraZeneca

Phase 3 Active not recruiting
1,889 enrolled
Genitourinary

Prostatic Neoplasms

NCT05348876 2026-05-18

A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)

Bayer

Phase 4 Recruiting
50 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡